Journal of Natural Medicines

, Volume 71, Issue 4, pp 757–764 | Cite as

Effect of ninjin’yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice

  • Toshiaki Suzuki
  • Ayano Yamamoto
  • Masahiro Ohsawa
  • Yoshiharu Motoo
  • Hajime Mizukami
  • Toshiaki Makino
Original Paper

Abstract

Oxaliplatin (L-OHP) is a platinum-based anticancer agent used to treat various types of cancer. It frequently causes acute and chronic peripheral neuropathies, such as cold allodynia and mechanical hyperalgesia. Ninjin’yoeito (NYT) is a formula used in traditional Japanese Kampo medicine to improve recovery from diseases and other medical disorders. We previously reported that treatment with a boiling-water extract of NYT prevented L-OHP-induced damage to neurite-like outgrowths from differentiated PC12 cells. The objectives of the present study were to evaluate the in vivo effects of NYT on L-OHP-induced neuropathic pain in mice and identify the active ingredients in NYT. Treatment with NYT extract significantly ameliorated both cold allodynia and mechanical hyperalgesia induced by L-OHP. While L-OHP treatment suppressed neurite outgrowths from primary dorsal root ganglion cells in vitro, NYT extract blocked this suppression in a concentration-dependent manner. Among the herbal components of NYT, the extract of ginseng (Panax ginseng roots) showed a protective effect against neurite damage induced by L-OHP, and one of its active ingredients was identified as ginsenoside Rg3. Ginseng extract partially relieved L-OHP-induced neuropathic pain in mice. Our results suggest that NYT could be an attractive agent for treating L-OHP-induced neuropathic pain, and that the active ingredient of NYT may be ginseng.

Keywords

Oxaliplatin Neuropathy Ninjin’yoeito Root of Panax ginseng Ginsenoside Rg3 

Notes

Acknowledgements

This research was supported by Grant-in-Aid for Scientific Research (KAKENHI) C #16K09267 (2016), and the Kidani Memorial Trust (2016).

References

  1. 1.
    Grothey A, Goldberg RM (2004) A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 5:2159–2170CrossRefPubMedGoogle Scholar
  2. 2.
    Qvortrup C, Yilmaz M, Ogreid D, Berglund A, Balteskard L, Ploen J, Fokstuen T, Starkhammar H, Sorbye H, Tveit K, Pfeiffer P (2008) Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Ann Oncol 19:1154–1159CrossRefPubMedGoogle Scholar
  3. 3.
    Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Boige V, Berille J, Conroy T (2013) Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncology 31:23–29CrossRefGoogle Scholar
  4. 4.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46Google Scholar
  5. 5.
    Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K (2013) Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 14:1278–1286CrossRefPubMedGoogle Scholar
  6. 6.
    Pasetto LM, D’Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59:159–168CrossRefPubMedGoogle Scholar
  7. 7.
    Carozzi VA, Canta A, Chiorazzi A, Cavaletti G (2014) Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett 596:90–107CrossRefPubMedGoogle Scholar
  8. 8.
    Bensky D, Clavey S, Stöger E (2004) Chinese herbal medicine—materia medica, 3rd edn. Eastland, SeattleGoogle Scholar
  9. 9.
    Suzuki T, Yamamoto A, Ohsawa M, Motoo Y, Mizukami H, Makino T (2015) Ninjin’yoeito and ginseng extract prevent oxaliplatin-induced neurodegeneration in PC12 cells. J Nat Med 69:531–537CrossRefPubMedGoogle Scholar
  10. 10.
    The Society of Japanese Pharmacopoeia (2016) The Japanese pharmacopoeia seventeenth edition (JPXVII). Yakuji-Nippo, TokyoGoogle Scholar
  11. 11.
    Gao S, Kushida H, Makino T (2017) Ginsenosides, ingredients of the root of Panax ginseng, are not substrates but inhibitors of sodium-glucose transporter 1. J Nat Med 71:131–138CrossRefPubMedGoogle Scholar
  12. 12.
    Ohsawa M, Otake S, Murakami T, Yamamoto S, Makino T, Ono H (2014) Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice. J Pharmacol Sci 125:292–299CrossRefPubMedGoogle Scholar
  13. 13.
    Suzuki T, Miyamoto K, Yokoyama N, Sugi M, Kagioka A, Kitao Y, Adachi T, Ohsawa M, Mizukami H, Makino T (2016) Processed aconite root and its active ingredient neoline may alleviate oxaliplatin-induced peripheral neuropathic pain. J Ethnopharmacol 186:44–52CrossRefPubMedGoogle Scholar
  14. 14.
    Dixon WJ (1980) Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20:441–462CrossRefPubMedGoogle Scholar
  15. 15.
    Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55–63CrossRefPubMedGoogle Scholar
  16. 16.
    Ushio S, Egashira N, Sada H, Kawashiri T, Shirahama M, Masuguchi K, Oishi R (2012) Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur J Cancer 48:1407–1413CrossRefPubMedGoogle Scholar
  17. 17.
    Kitamura R, Andoh T, Fushimi H, Komatsu K, Shibahara N, Kuraishi Y (2013) Involvement of descending monoaminergic systems in antiallodynic effect of goshajinkigan in oxaliplatin-treated mice. J Tradit Med 30:183–189Google Scholar
  18. 18.
    Mizuno K, Kono T, Suzuki Y, Miyagi C, Omiya Y, Miyano K, Kase Y, Uezono Y (2014) Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. J Pharmacol Sci 125:91–98CrossRefPubMedGoogle Scholar
  19. 19.
    Mizuno K, Shibata K, Komatsu R, Omiya Y, Kase Y, Koizumi S (2016) An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi. Cancer Biol Ther 17:1206–1212CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kato Y, Tateai Y, Ohkubo M, Saito Y, Amagai SY, Kimura YS, Iimura N, Okada M, Matsumoto A, Mano Y, Hirosawa I, Ohuchi K, Tajima M, Asahi M, Kotaki H, Yamada H (2014) Gosha-jinki-gan reduced oxaliplatin-induced hypersensitivity to cold sensation and its effect would be related to suppression of the expression of TRPM8 and TRPA1 in rats. Anticancer Drugs 25:39–43CrossRefPubMedGoogle Scholar
  21. 21.
    Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y (2015) Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20:767–775Google Scholar
  22. 22.
    Ahn BS, Kim SK, Kim HN, Lee JH, Lee JH, Hwang DS, Bae H, Min BI, Kim SK (2014) Gyejigachulbu-tang relieves oxaliplatin-induced neuropathic cold and mechanical hypersensitivity in rats via the suppression of spinal glial activation. Evid Based Complement Altern Med 2014:436482CrossRefGoogle Scholar
  23. 23.
    Deng B, Jia L, Pan L, Song A, Wang Y, Tan H, Xiang Q, Yu L, Ke D (2016) Wen-Luo-Tong prevents glial activation and nociceptive sensitization in a rat model of oxaliplatin-induced neuropathic pain. Evid Based Complement Altern Med 2016:3629489Google Scholar
  24. 24.
    Andoh T, Mizoguchi S, Kuraishi Y (2017) Shakuyakukanzoto attenuates oxaliplatin-induced cold dysesthesia by inhibiting the expression of transient receptor potential melastatin 8 in mice. J Tradit Complement Med 7:30–33CrossRefPubMedGoogle Scholar
  25. 25.
    Gauchan P, Andoh T, Kato A, Sasaki A, Kuraishi Y (2009) Effects of the prostaglandin E1 analog limaprost on mechanical hyperalgesia caused by chemotherapeutic agents in mice. J Pharm Sci 109:469–472CrossRefGoogle Scholar
  26. 26.
    Pang H, Wang HL, Fu L, Su CY (2001) Pharmacokinetic studies of 20(R)-ginsenoside Rg3 in human volunteers. Acta Pharma Sin 36:170–173Google Scholar
  27. 27.
    Kim C, Lee JH, Kim W, Li D, Kim Y, Lee K, Kim SK (2016) The suppressive effects of cinnamomi cortex and its phytocompound coumarin on oxaliplatin-induced neuropathic cold allodynia in rats. Molecules 21:E1253Google Scholar
  28. 28.
    Di Cesare Mannelli L, Pacini A, Micheli L, Femia AP, Maresca M, Zanardelli M, Vannacci A, Gallo E, Bilia AR, Caderni G, Firenzuoli F, Mugelli A, Ghelardini C (2017) Astragali radix: could it be an adjuvant for oxaliplatin-induced neuropathy? Sci Rep 7:42021CrossRefGoogle Scholar
  29. 29.
    Wang CZ, Yuan CS (2008) Potential role of ginseng in the treatment of colorectal cancer. Am J Chin Med 36:1019–1028CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK, Tang W (2010) Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trend 4:297–307Google Scholar

Copyright information

© The Japanese Society of Pharmacognosy and Springer Japan KK 2017

Authors and Affiliations

  • Toshiaki Suzuki
    • 1
    • 2
  • Ayano Yamamoto
    • 1
  • Masahiro Ohsawa
    • 3
  • Yoshiharu Motoo
    • 4
  • Hajime Mizukami
    • 1
    • 5
  • Toshiaki Makino
    • 1
  1. 1.Department of Pharmacognosy, Graduate School of Pharmaceutical SciencesNagoya City UniversityNagoyaJapan
  2. 2.Department of Cellular Pharmacology, Graduate School of Pharmaceutical SciencesNagoya UniversityNagoyaJapan
  3. 3.Department of NeuropharmacologyGraduate School of Pharmaceutical SciencesNagoyaJapan
  4. 4.Department of Medical OncologyKanazawa Medical UniversityUchinadaJapan
  5. 5.The Kochi Prefectural Makino Botanical GardenKochiJapan

Personalised recommendations